Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
Rheumatol Ther. 2022. Epub ahead of print doi: 10.1007/s40744-022-00507-z
This post-hoc analysis of 31 clinical trials in ulcerative colitis, rheumatoid arthritis and psoriatic arthritis concludes that combined influenza adverse event incidence rates were highest in ulcerative colitis, while in each indication they were generally similar across tofacitinib, placebo, and comparator groups.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has further heightened the need to better understand the overall risk of acute respiratory viral infections, including influenza, in patients with immune-mediated inflammatory diseases receiving long-term immunosuppressive treatment such as tofacitinib. To this end, Winthrop, et al. evaluated influenza adverse events across several immune-mediated inflammatory diseases, in the tofacitinib clinical development programme.